According to a 2025 joint advisory from the American College of Lifestyle Medicine (ACLM), American Society for Nutrition (ASN), Obesity Medicine Association (OMA), and The Obesity Society (TOS), diarrhea during glucagon-like peptide 1 receptor agonists (GLP-1) therapy is managed primarily through supportive and dietary strategies, particularly during initiation and dose escalation. Recommended measures include avoiding large or high-fat meals and maintaining adequate hydration to reduce symptom severity and prevent complications such as dehydration. If significant diarrhea occurs, fiber supplementation (capsules or powders) may be used to add stool bulk, and antidiarrheal medications may provide acute symptom relief. The advisory also highlights the role of gradual dose escalation and maintaining patients at the lowest effective dose to improve gastrointestinal tolerability. Similarly, a 2022 multidisciplinary expert consensus indicates that diarrhea is typically transient and managed with hydration, dietary modification, and dose-adjustment strategies. Additional recommendations include avoiding dietary triggers such as high-fat foods, dairy, caffeine, alcohol, sweeteners ending in “-ol,” and high-fiber foods during active symptoms, while using easily digestible foods. In cases of persistence despite these measures, probiotic and/or antidiarrheal agents such as loperamide may be considered, along with dose-escalation delay, dose reduction, or temporary interruption. Specific recommendations regarding loperamide dosing or duration were not described. [1], [2]
A 2022 review on managing gastrointestinal (GI) adverse effects of GLP-1 receptor agonists highlights that GI symptoms are common in patients with overweight or obesity and may worsen with treatment initiation, necessitating proactive patient counseling on symptom management, including the short-term use of over-the-counter therapies (e.g., for diarrhea). Pharmacologic interventions used during dose titration should not be continued long term; if GI symptoms persist beyond approximately one month at the maintenance dose and require ongoing treatment, dose reduction to a more tolerable level should be considered. In cases where patients are unable to tolerate even low doses, discontinuation of the GLP-1 receptor agonist is recommended. Switching to an alternative GLP-1 receptor antagonist may be reasonable due to differences in tolerability profiles, with reinitiation following symptom resolution (which may take several days to weeks) and standard dose-escalation protocols. If intolerance persists despite these strategies, transitioning to a different class of obesity pharmacotherapy may be appropriate. [3]
The 2024 publication of the SURMOUNT-4 randomized clinical trial explores the long-term effects of continued treatment with tirzepatide in maintaining weight reduction in adults with obesity. Conducted across 70 sites in four countries, this phase 3 trial included an initial 36-week open-label period during which 783 participants received the maximum tolerated dose (10 or 15 mg) of tirzepatide administered subcutaneously once weekly. Within the trial protocol, persistent gastrointestinal adverse effects, including diarrhea, were managed using a stepwise approach. Patients experiencing intolerable symptoms were first counseled on dietary modifications, such as consuming smaller, more frequent meals and stopping intake when full. If symptoms persisted, investigators could initiate symptomatic therapies (e.g., antidiarrheals) at their discretion; however, no specific antidiarrheal agents were recommended in the protocol. A temporary one-dose interruption was permitted if the prior three doses had been administered, after which treatment was resumed with or without supportive medications. For ongoing intolerance despite these measures, investigators could consider dose de-escalation with subsequent re-escalation in consultation with the sponsor. Patients with persistent, intolerable symptoms despite all interventions were required to discontinue the study drug but remained in the trial for continued follow-up. [4]
A 2023 meta-analysis of 8 randomized controlled trials (N= 7,626) examined gastrointestinal adverse events associated with tirzepatide and found that diarrhea is a common adverse effect with dose-related incidence, reported at approximately 4.0% with 5 mg, 15.1% with 10 mg, and 19.2% with 15 mg in placebo-controlled analyses. Compared with insulin, diarrhea risk was significantly increased across all doses (relative risk [RR] 3.27 to 4.60). Compared with GLP-1 receptor agonists, results were variable, with a significantly higher risk observed at tirzepatide 10 mg (RR 1.40, 95% confidence interval [CI] 1.06 to 1.85), while differences at 5 mg and 15 mg were not consistently significant. The analysis also references individual trials with 26-week and 40-week durations, noting lower rates of gastrointestinal adverse events, including diarrhea, in longer-duration studies, with findings indicating that these events decrease over time with continued treatment, although specific timing for improvement was not defined. Therefore, the authors concluded that long-term steady medication may be expected to reduce gastrointestinal adverse events. [5]